In silico Study of New Vascular Endothelial Growth Factor Receptor Inhibitors for The Treatment of Hepatocellular Carcinoma
Al Mustansiriyah Journal of Pharmaceutical Sciences · 2023
DOI: 10.32947/ajps.v23i2.1023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Al Mustansiriyah Journal of Pharmaceutical Sciences, 2023. Verfasst von Marwan Imad Jihad und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Novel therapeutics are desperately needed for the difficult-to-treat and very lethal malignancy known as hepatocellular carcinoma (HCC). The first drug now authorized for the treatment of individuals with advanced HCC is sorafenib. To find novel Vascular Endothelial Growth Factor Receptor Inhibitors as prospective candidate therapeutics for HCC, an in-silico technique was used in this case. Docking investigations were conducted using the GOLD Suite (v. 5.7.1) from the Cambridge Crystallographic Data Centre (CCDC). The docking/scoring methods of CCDC were validated by reproducing the docking interactions and poses of Sorafenib. Based on their PLP fitness, compounds I–X and sorafenib were graded for their ability to inhibit VEGF. Compounds II, III and VIII among other ligands exhibit higher binding energies than the standard drug sorafenib that give PLP fitness value (80.4).
Zitieren
APA
Jihad, M. I., & Mahdi, M. F. (2023). In silico Study of New Vascular Endothelial Growth Factor Receptor Inhibitors for The Treatment of Hepatocellular Carcinoma. Al Mustansiriyah Journal of Pharmaceutical Sciences. https://doi.org/10.32947/ajps.v23i2.1023
Vancouver
Jihad MI, Mahdi MF. In silico Study of New Vascular Endothelial Growth Factor Receptor Inhibitors for The Treatment of Hepatocellular Carcinoma. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2023. doi:10.32947/ajps.v23i2.1023
BibTeX
@article{Jihad2023,
author = {Jihad, Marwan Imad and Mahdi, Monther Faisal},
title = {In silico Study of New Vascular Endothelial Growth Factor Receptor Inhibitors for The Treatment of Hepatocellular Carcinoma},
journal = {Al Mustansiriyah Journal of Pharmaceutical Sciences},
year = {2023},
doi = {10.32947/ajps.v23i2.1023}
}
EUVIMED